688192 迪哲医药
已收盘 12-23 15:00:00
资讯
新帖
简况
迪哲医药将于12月27日解禁418万股限售股
财中社 · 12-19
迪哲医药将于12月27日解禁418万股限售股
迪哲医药定增事项获得上交所审核通过
北京商报 · 12-11
迪哲医药定增事项获得上交所审核通过
迪哲医药型肺癌靶向药舒沃哲研究成果获《Lung Cancer》发表
财中社 · 12-11
迪哲医药型肺癌靶向药舒沃哲研究成果获《Lung Cancer》发表
上交所审核通过迪哲医药再融资 支持新质生产力发展
新浪科技 · 12-11
上交所审核通过迪哲医药再融资 支持新质生产力发展
迪哲医药：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表
证券之星 · 12-11
迪哲医药：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表
迪哲医药(688192.SH)向特定对象发行A股股票申请获上交所审核通过
智通财经 · 12-11
迪哲医药(688192.SH)向特定对象发行A股股票申请获上交所审核通过
迪哲医药(688192.SH)：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表
智通财经 · 12-11
迪哲医药(688192.SH)：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表
迪哲医药：DZD8586最新研究成果在2024 ASH大会报告
证券之星 · 12-09
迪哲医药：DZD8586最新研究成果在2024 ASH大会报告
迪哲医药(688192.SH)：研究显示DZD8586具有良好的抗肿瘤活性
智通财经 · 12-09
迪哲医药(688192.SH)：研究显示DZD8586具有良好的抗肿瘤活性
IPO募资21亿元 三年后迪哲医药拟再融资18亿元
中国经营报 · 12-01
IPO募资21亿元 三年后迪哲医药拟再融资18亿元
迪哲医药-U大涨 国谈创新药成功
智选洞察 · 11-29
迪哲医药-U大涨 国谈创新药成功
迪哲医药（688192）股东张小林质押277.16万股，占总股本0.67%
证券之星 · 11-28
迪哲医药（688192）股东张小林质押277.16万股，占总股本0.67%
迪哲医药董事长张小林质押277万股 用于融资担保
财中社 · 11-28
迪哲医药董事长张小林质押277万股 用于融资担保
迪哲医药：自主研发的两款创新药物纳入新版国家医保药品目录
证券之星 · 11-28
迪哲医药：自主研发的两款创新药物纳入新版国家医保药品目录
迪哲医药(688192.SH)部分创新药纳入新版国家医保药品目录
智通财经 · 11-28
迪哲医药(688192.SH)部分创新药纳入新版国家医保药品目录
1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会
汇添富基金 · 11-28
1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会
迪哲医药下调募资金额 新药研发项目投资大幅下降
新京报 · 11-27
迪哲医药下调募资金额 新药研发项目投资大幅下降
迪哲医药发布定增预案修订稿 拟募资18.48亿加速新药研发
财中社 · 11-24
迪哲医药发布定增预案修订稿 拟募资18.48亿加速新药研发
迪哲医药-U跌5% 10家券商看好
智选洞察 · 11-22
迪哲医药-U跌5% 10家券商看好
迪哲医药-U大涨 论坛聚焦医药创新
智选洞察 · 11-21
迪哲医药-U大涨 论坛聚焦医药创新
暂无数据
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":42.33,"timestamp":1734937200000,"preClose":42.83,"halted":0,"volume":2133320,"delay":0,"floatShares":123000000,"shares":416000000,"eps":-2.0143,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.5,"latestTime":"12-23 15:00:00","open":42.55,"high":43.15,"low":41.61,"amount":90284300,"amplitude":0.036,"askPrice":42.43,"askSize":2,"bidPrice":42.33,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-2.0143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":42.83,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":47.11,"lowLimit":38.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":415653120,"pbRate":41.07,"roa":"--","roe":"--","epsLYR":-2.72,"committee":0.801242,"marketValue":17595000000,"floatMarketCap":5210000000,"peRate":-21.014743,"changeRate":-0.0117,"turnoverRate":0.0173,"status":1,"afterMarket":{"amount":0,"volume":0,"close":42.33,"buyVolume":0,"sellVolume":0,"time":1734939238975,"indexStatus":"已收盘 12-23 15:30:00","preClose":42.83}},"requestUrl":"/m/hq/s/688192/tweets","defaultTab":"tweets","newsList":[{"id":"2492034126","title":"迪哲医药将于12月27日解禁418万股限售股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492034126","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492034126?lang=zh_cn&edition=full","pubTime":"2024-12-19 19:26","pubTimestamp":1734607560,"startTime":"0","endTime":"0","summary":"财中社12月19日电迪哲医药 发布关于2020年员工股份期权计划第一个行权期行权限售股上市流通的公告。此次上市流通的股数为418万股，上市流通日期定于2024年12月27日。公告中提到，自2020年员工股份期权计划实施以来，公司总股本已由4亿股变更为4.16亿股，新增股份共计1210万股。此次申请上市流通的限售股占公司总股本的比例为1.01%。2024年前三季度，迪哲医药-U实现收入3.38亿元，归母净利润-5.58亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-19/doc-inczzcmp9924203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2490772861","title":"迪哲医药定增事项获得上交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2490772861","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490772861?lang=zh_cn&edition=full","pubTime":"2024-12-11 20:30","pubTimestamp":1733920237,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）12月11日晚间，迪哲医药（688192）发布公告称，公司于12月11日收到上交所出具的《关于迪哲（江苏）医药股份有限公司向特定对象发行股票的交易所审核意见》，公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。上交所将在收到公司申请文件后提交中国证监会注册。据了解，这是自“科八条”发布以来，上交所首家未盈利企业再融资获审核通过。文章来源：北京商报文章作者：丁宁原标题：迪哲医药定增事项获得上交所审核通过","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211205012ab6f9419&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211205012ab6f9419&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2490675898","title":"迪哲医药型肺癌靶向药舒沃哲研究成果获《Lung Cancer》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2490675898","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490675898?lang=zh_cn&edition=full","pubTime":"2024-12-11 18:04","pubTimestamp":1733911485,"startTime":"0","endTime":"0","summary":"财中社12月11日电迪哲医药 发布自愿披露公告，介绍其自主研发的肺癌靶向药舒沃哲在最新研究中取得的成果。该研究为I/II期临床研究的汇总分析，发表于《Lung Cancer》期刊，表明舒沃哲在治疗EGFR-TKI耐药的非小细胞肺癌患者中展现出良好的抗肿瘤活性和安全性。公司表示，该研究成果对近期业绩不会产生重大影响，提醒投资者注意研发药品的高风险和不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211181947a1e5e1cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211181947a1e5e1cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2490483675","title":"上交所审核通过迪哲医药再融资 支持新质生产力发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2490483675","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490483675?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:31","pubTimestamp":1733909460,"startTime":"0","endTime":"0","summary":"12月11日，迪哲医药公告显示，迪哲医药的科创板定向增发方案已经获上交所审核通过。这是证监会《关于深化科创板改革 服务科技创新和新质生产力发展的八条措施》发布以来，上交所首家未盈利企业再融资获得审核通过。迪哲医药表示，公司本次再融资将有助于公司进一步加速产品研发和生产基地建设，打造新质生产力，落实国家重大战略，推动产品出海，为生物医药经济发展赋予科创动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2024-12-11/doc-inczarzk7582701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["162717","688192","BK0239"],"gpt_icon":0},{"id":"2490838153","title":"迪哲医药：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2490838153","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490838153?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:40","pubTimestamp":1733906447,"startTime":"0","endTime":"0","summary":"迪哲医药公告，公司自主研发的新型肺癌靶向药舒沃哲的一项I/II期临床研究的汇总分析最新数据，发表于《Lung Cancer》。研究表明，舒沃哲单药治疗EGFR-TKI耐药的非小细胞肺癌患者具有良好的抗肿瘤活性和安全性。研究共纳入40例EGFR-TKI耐药晚期非小细胞肺癌患者，舒沃哲单药治疗EGFR-TKI耐药的非小细胞肺癌具有良好的抗肿瘤活性和安全性。公司提示，本次研究成果对公司近期业绩不会产生重大影响，投资者需谨慎决策，注意防范投资风险。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100026978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2490106887","title":"迪哲医药(688192.SH)向特定对象发行A股股票申请获上交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2490106887","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490106887?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:03","pubTimestamp":1733904218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2024年12月11日收到上海证券交易所出具的《关于迪哲(江苏)医药股份有限公司向特定对象发行股票的交易所审核意见》。具体意见如下：迪哲(江苏)医药股份有限公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注册。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","399300","688192","BK0239"],"gpt_icon":0},{"id":"2490951887","title":"迪哲医药(688192.SH)：舒沃哲单药治疗EGFR-TKI耐药非小细胞肺癌最新研究成果获《Lung Cancer》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2490951887","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490951887?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:01","pubTimestamp":1733904109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，近日，公司自主研发的新型肺癌靶向药舒沃哲®(通用名：舒沃替尼片)的一项I/II期临床研究的汇总分析最新数据，发表于欧洲肿瘤内科学会(ESMO)官方期刊《Lung Cancer》。研究表明，舒沃哲®单药治疗表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)耐药的非小细胞肺癌(NSCLC)患者具有良好的抗肿瘤活性和安全性。舒沃哲®于2023年8月在国内获批上市，是目前表皮生长因子受体(EGFR)20号外显子插入突变(Exon20ins)非小细胞肺癌(NSCLC)二/后线唯一标准治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2490107187","title":"迪哲医药：DZD8586最新研究成果在2024 ASH大会报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2490107187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490107187?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:12","pubTimestamp":1733731948,"startTime":"0","endTime":"0","summary":"迪哲医药公告，公司在第66届美国血液学会（ASH）大会上，公布了自主研发的全新非共价LYN/BTK双靶点抑制剂DZD8586治疗B细胞非霍奇金淋巴瘤（B-NHL）的疗效和安全性汇总分析的最新研究成果。DZD8586能够克服经典BTK耐药突变（C481X）和BTK激酶失活突变，治疗B-NHL表现出令人鼓舞的抗肿瘤疗效，良好的安全性与药代动力学（PK）特征。研究结果显示，DZD8586具有良好的抗肿瘤活性、安全性可控，临床可管理，以及良好的药代动力学特性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120900020073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2490712931","title":"迪哲医药(688192.SH)：研究显示DZD8586具有良好的抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=2490712931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490712931?lang=zh_cn&edition=full","pubTime":"2024-12-09 15:40","pubTimestamp":1733730050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司在第66届美国血液学会(ASH)大会上，公布了公司自主研发的全新非共价LYN/BTK双靶点抑制剂DZD8586治疗B细胞非霍奇金淋巴瘤(B-NHL)的疗效和安全性汇总分析的最新研究成果，DZD8586能够克服经典BTK耐药突变(C481X)和BTK激酶失活突变，治疗B-NHL表现出令人鼓舞的抗肿瘤疗效，良好的安全性与药代动力学(PK)特征。研究结果显示，截至2024年10月20日，DZD8586治疗复发难治性(r/r)B-NHL：1、具有良好的抗肿瘤活性;2、安全性可控，临床可管理;3、良好的药代动力学(PK)特性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2488687968","title":"IPO募资21亿元 三年后迪哲医药拟再融资18亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488687968","media":"中国经营报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488687968?lang=zh_cn&edition=full","pubTime":"2024-12-01 07:28","pubTimestamp":1733009280,"startTime":"0","endTime":"0","summary":"2021年年底，迪哲医药IPO上市，募集资金总额21亿元、募集资金净额19.9亿元。不过，截至2024年三季度末，公司仅有1.31亿元的货币资金及6.77亿元的交易性金融资产，长短期借款合计约8.2亿元。截至2024年6月30日，公司累计使用募集资金15.49亿元，其中以前年度累计使用募集资金14.03亿元。迪哲医药此次再融资，与创新药的高投入不无关系。2024年前三季度，迪哲医药研发投入合计5.68亿元，占营收比例为167.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-01/doc-incxxfvv0066356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688192","BK0239","162717"],"gpt_icon":0},{"id":"2487305517","title":"迪哲医药-U大涨 国谈创新药成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2487305517","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487305517?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:27","pubTimestamp":1732850857,"startTime":"0","endTime":"0","summary":"11月29日，迪哲医药-U股价大幅上涨，截至11点27分，迪哲医药-U上涨5.15%，报50.20元/股，创近1个月新高，突破50元整数关口，成交1.70亿元，换手率2.82%。资金动向截止发稿，迪哲医药-U获得主力净流出798万元，其中超大单流入212万元，大单流出1010万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129112850a25e0bbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129112850a25e0bbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","159992","BK0239"],"gpt_icon":0},{"id":"2486316031","title":"迪哲医药（688192）股东张小林质押277.16万股，占总股本0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486316031","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486316031?lang=zh_cn&edition=full","pubTime":"2024-11-28 21:20","pubTimestamp":1732800031,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药11月28日公开信息显示，股东张小林向华能贵诚信托有限公司合计质押277.16万股，占总股本0.67%。质押详情见下表：截止本公告日，股东ZYTZ Partners Limited已累计质押股份389.0万股，占其持股总数的75.28%。迪哲医药主营业务：创新药的研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800037031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2486673113","title":"迪哲医药董事长张小林质押277万股 用于融资担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2486673113","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486673113?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:49","pubTimestamp":1732783740,"startTime":"0","endTime":"0","summary":"财中社11月28日电迪哲医药 发布关于股东部分股份质押的公告。公告显示，董事长兼首席执行官张小林博士直接持有公司股份731万股，占公司总股本的1.76%。此次质押的股份为277万股，占其直接持股数量的37.91%，占公司总股本的0.67%。质押起始日为2024年11月27日，质权人为华能贵诚信托有限公司，质押融资资金用途为融资担保。此次质押股份未被用作重大资产重组、业绩补偿等事项担保。2024年前三季度，迪哲医药-U实现收入3.38亿元，归母净利润-5.58亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128165216a25bf1de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128165216a25bf1de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2486364637","title":"迪哲医药：自主研发的两款创新药物纳入新版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486364637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486364637?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:09","pubTimestamp":1732781350,"startTime":"0","endTime":"0","summary":"迪哲医药公告，公司自主研发的两款创新药物舒沃哲®（通用名：舒沃替尼片）和高瑞哲®（通用名：戈利昔替尼胶囊）成功纳入新版国家医保药品目录，该目录将于2025年1月1日起正式实施。舒沃哲®是EGFR Exon20ins NSCLC二/后线唯一标准治疗方案，填补了该领域近20年临床空白。高瑞哲®是全球首个且唯一治疗PTCL高选择性JAK1抑制剂，打破了PTCL全球十年无创新药的困局。两款药物纳入医保目录有助于提高患者可负担性和可及性，降低用药负担，对公司长期经营发展具有积极影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800024425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK1574","BK1161","688192","BK0239"],"gpt_icon":0},{"id":"2486366717","title":"迪哲医药(688192.SH)部分创新药纳入新版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486366717","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486366717?lang=zh_cn&edition=full","pubTime":"2024-11-28 15:42","pubTimestamp":1732779730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》的通知，公司自主研发的两款源头创新药物舒沃哲®(通用名：舒沃替尼片)和高瑞哲®(通用名：戈利昔替尼胶囊)成功纳入国家医保药品目录，该目录将于2025年1月1日起正式实施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK1161","159992","06978","BK0239","BK1574"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688658","BK0096","688046","688373","600566","603233","688189","688488","159938","BK0070","600572","688321","600511","688271","688137","600771","600196","603367","600521","603707","600422","688212","600851","688578","688266","600721","BK0185","603439","688315","603567","600211","688235","688221","600535","688091","688690","600085","688085","603259","600080","688443","600420","688176","600055","600329","688192","600285","688575","688105","603858","603392","603896","600351","600161","688617","688356","688389","688161","688298","600763","688351","603658","688117","600739","600529","688656","688336","688520","603309","688076","600252","688193","600436","600062","688073","603456","688331","688050","688301","600276","600998","600867","688382","688198","688114","688067","603590","688139","688506","603882","600380","688670","603108","688687","688222","688767","BK0188","600056","688177","603301","603127","BK0012","600488","605199","601607","688029","688276","688581","600976","603538","688166","600129","600200","688247","688180","688566","688163","603939","605177","603087","BK0239","600332","688202","688278","688062","688626","BK0028","688428","600079"],"gpt_icon":0},{"id":"2486286501","title":"迪哲医药下调募资金额 新药研发项目投资大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2486286501","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486286501?lang=zh_cn&edition=full","pubTime":"2024-11-27 09:42","pubTimestamp":1732671726,"startTime":"0","endTime":"0","summary":"募集资金投资项目并没有变化，新药研发项目投资金额大幅降低。迪哲医药并未给出下调原因。募资金额下调约29%早在2023年3月，迪哲医药披露2023年度向特定对象发行A股股票预案，计划募资金额最高不超过26.08亿元，分别用于新药研发项目、国际标准创新药产业化项目，以及补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127094331a25878cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127094331a25878cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2485767752","title":"迪哲医药发布定增预案修订稿 拟募资18.48亿加速新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2485767752","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485767752?lang=zh_cn&edition=full","pubTime":"2024-11-24 18:30","pubTimestamp":1732444247,"startTime":"0","endTime":"0","summary":"财中社11月24日电迪哲医药 发布2023年度向特定对象发行A股股票预案（修订稿）。公司计划募集资金总额不超过18.48亿元，主要用于新药研发项目、国际标准创新药产业化项目以及补充流动资金（2亿元）。本次发行的股票数量上限为4157万股，不超过公司总股本的10%。2024年前三季度，迪哲医药-U实现收入3.38亿元，归母净利润-5.58亿元。文章来源：财中社迪哲医药发布定增预案修订稿 拟募资18.48亿加速新药研发","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241124184916abdb2667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241124184916abdb2667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2485893702","title":"迪哲医药-U跌5% 10家券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2485893702","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485893702?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:36","pubTimestamp":1732257387,"startTime":"0","endTime":"0","summary":"11月22日，迪哲医药-U股价大幅下跌，截至14点36分，迪哲医药-U下跌5.03%，报45.50元/股，成交9515万元，换手率1.65%。资金动向截止发稿，迪哲医药-U获得主力净流入197万元，其中超大单流出652万元，大单流入850万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。最新财报显示，今年三季报，迪哲医药-U实现营业收入3.38亿元，同比增长743.97%，净利润为-5.58亿元，同比增长32.63%，基本每股收益为-1.35元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122143651a24d2909&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122143651a24d2909&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2485072601","title":"迪哲医药-U大涨 论坛聚焦医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2485072601","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485072601?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:43","pubTimestamp":1732153396,"startTime":"0","endTime":"0","summary":"11月21日，迪哲医药-U股价大幅上涨，截至09点43分，迪哲医药-U上涨5.23%，报49.10元/股，成交6342万元，换手率1.07%，振幅5.81%。资金动向截止发稿，迪哲医药-U获得主力净流出620万元，其中超大单流出93万元，大单流出525万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121094341a249f48d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121094341a249f48d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159938","688192"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","stockEarnings":[{"period":"1week","weight":-0.0658},{"period":"1month","weight":-0.0614},{"period":"3month","weight":0.2312},{"period":"6month","weight":0.0744},{"period":"1year","weight":-0.0371},{"period":"ytd","weight":-0.1154}],"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","perCapita":"14726股","boardName":"医药制造业","registeredCapital":"41565万元","compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"survey":" 迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。","serverTime":1734998614630,"listedPrice":52.58,"stockholders":"8642人(较上一季度增加1.99%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}